NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
LOS ANGELES, March 31, 2017 -- Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (Nasdaq:SCYX) concerning possible violations of federal securities laws. Investors who purchased SCYNEXIS securities: (1) pursuant or traceable to the Company’s initial public offering on or about May 2, 2014; and/or (2) from May 2, 2014 through March 2, 2017, inclusive (the “Class Period”) should contact the firm prior to the May 8, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The complaint states that during the Class Period, SCYNEXIS made false and/or misleading statements and/or failed to disclose: that the Company’s lead product, SCY-078, posed substantial undisclosed health and safety risks; that SCYNEXIS overstated the drug’s approval prospects and/or commercial viability; and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times.
On March 2, 2017, SCYNEXIS announced that the U.S. Food and Drug Administration “informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data” of the formulation. The hold stems from “three mild-to-moderate thrombotic events in healthy volunteers” receiving the formulation. When this information reached the investing public, shares of SCYNEXIS dropped in value, causing investors harm.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
